Skip to main content
All lobbying filings

CORMEDIX INC.

Lobbying for CORMEDIX INC. · Biopharmaceutical company.

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 31, 2026
Expenses
$220,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
New Jersey

Official filing document

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 4
 Lobbying activity 1
Health Issues

H.R. 6214/S. 2730, Kidney Care Access Protection Act, including provisions related to healthcare and Medicare H.R. 7352/S. 4815, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem